Login to Your Account



Amylin's Long-Awaited Therapy For Lipodystrophy Goes to FDA

By Catherine Shaffer
Staff Writer

Wednesday, April 4, 2012
Nearly eclipsed by the lengthy approval process for Bydureon (exenatide once-weekly), Amylin Pharmaceuticals Inc.'s metreleptin (recombinant methionyl human leptin) in diabetes lipodystrophy may soon get its moment in the sun.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription